AESGP targets digital future
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
The Association of the European Self medication Industry (AESGP) has had to take a hard look at where it needed to get involved when it came to the rising influence of the digital ecosystem on healthcare, Hubertus Cranz, director general of the association, told the AESGP Conference with the Heads of European Union (EU) Medicines Agencies in Lisbon, Portugal.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.